Unwanted immunogenicity, its characteristics, and clinical significance is at present very difficult, if not impossible to predict based on simple models.
I am simply questioning the blanket statement that all phylomers, being up to 50mer, will have problems - this is not justified. Even some human antibody therapeutics can evoke a significant anti-body response.
Phylomer libraries are not drug libraries. Phylomers are screened for activity; to produce a drug requires further transformation (for stability, activity, anti-toxicity, etc.) - pharmacology properties.
I have a friend with a PhD from Harvard Medical School and UMASS where he worked as an oncologist and immunologist. I'll get his view on phylomer immunogenicity, phage display and yeast-two-hybrid screening technologies for peptides and report back to the thread.
- Forums
- ASX - By Stock
- Ann: Core patent granted in Australia
Unwanted immunogenicity, its characteristics, and clinical...
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PYC (ASX) to my watchlist
|
|||||
Last
11.5¢ |
Change
-0.005(4.17%) |
Mkt cap ! $536.5M |
Open | High | Low | Value | Volume |
12.0¢ | 12.5¢ | 11.5¢ | $376.2K | 3.094M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
11 | 228402 | 11.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
11.5¢ | 65494 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
11 | 228402 | 0.110 |
7 | 421819 | 0.105 |
11 | 858229 | 0.100 |
1 | 7221 | 0.099 |
5 | 201916 | 0.098 |
Price($) | Vol. | No. |
---|---|---|
0.115 | 65494 | 3 |
0.120 | 1050153 | 5 |
0.125 | 100600 | 3 |
0.130 | 1344102 | 21 |
0.135 | 507212 | 6 |
Last trade - 15.18pm 23/08/2024 (20 minute delay) ? |
Featured News
PYC (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online